Editas Medicine Net Income
| EDIT Stock | USD 1.78 0.03 1.66% |
As of the 11th of February 2026, Editas Medicine shows the Mean Deviation of 3.34, standard deviation of 4.65, and Variance of 21.64. Editas Medicine technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Editas Medicine Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 0.6512 | Revenue | Earnings Share (2.35) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -213.4 M | -202.7 M | |
| Net Loss | -213.4 M | -224.1 M | |
| Net Loss | -198.4 M | -188.5 M | |
| Net Loss | (3.31) | (3.48) | |
| Net Income Per E B T | 0.91 | 0.81 |
Editas | Net Income | Build AI portfolio with Editas Stock |
The evolution of Net Income for Editas Medicine provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Editas Medicine compares to historical norms and industry peers.
Latest Editas Medicine's Net Income Growth Pattern
Below is the plot of the Net Income of Editas Medicine over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Editas Medicine financial statement analysis. It represents the amount of money remaining after all of Editas Medicine operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Editas Medicine's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (237.09 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Editas Net Income Regression Statistics
| Arithmetic Mean | (110,262,895) | |
| Coefficient Of Variation | (74.21) | |
| Mean Deviation | 66,804,242 | |
| Median | (109,954,000) | |
| Standard Deviation | 81,831,483 | |
| Sample Variance | 6696.4T | |
| Range | 231.7M | |
| R-Value | (0.95) | |
| Mean Square Error | 653.1T | |
| R-Squared | 0.91 | |
| Slope | (15,446,446) | |
| Total Sum of Squares | 107142.3T |
Editas Net Income History
Other Fundumenentals of Editas Medicine
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Editas Medicine Net Income component correlations
Editas Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Editas Medicine is extremely important. It helps to project a fair market value of Editas Stock properly, considering its historical fundamentals such as Net Income. Since Editas Medicine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Editas Medicine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Editas Medicine's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Editas introduce new products? Factors like these will boost the valuation of Editas Medicine. Projected growth potential of Editas fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.35) | Revenue Per Share | Quarterly Revenue Growth 122.656 | Return On Assets | Return On Equity |
Editas Medicine's market price often diverges from its book value, the accounting figure shown on Editas's balance sheet. Smart investors calculate Editas Medicine's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Editas Medicine's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Editas Medicine's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Editas Medicine should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Editas Medicine 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Editas Medicine's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Editas Medicine.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Editas Medicine on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Editas Medicine or generate 0.0% return on investment in Editas Medicine over 90 days. Editas Medicine is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines t... More
Editas Medicine Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Editas Medicine's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Editas Medicine upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 26.68 | |||
| Value At Risk | (8.18) | |||
| Potential Upside | 7.54 |
Editas Medicine Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Editas Medicine's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Editas Medicine's standard deviation. In reality, there are many statistical measures that can use Editas Medicine historical prices to predict the future Editas Medicine's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.76) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (0.26) |
Editas Medicine February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.25) | |||
| Mean Deviation | 3.34 | |||
| Coefficient Of Variation | (821.23) | |||
| Standard Deviation | 4.65 | |||
| Variance | 21.64 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.76) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (0.26) | |||
| Maximum Drawdown | 26.68 | |||
| Value At Risk | (8.18) | |||
| Potential Upside | 7.54 | |||
| Skewness | 0.258 | |||
| Kurtosis | 1.56 |
Editas Medicine Backtested Returns
Editas Medicine secures Sharpe Ratio (or Efficiency) of -0.1, which denotes the company had a -0.1 % return per unit of risk over the last 3 months. Editas Medicine exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Editas Medicine's Variance of 21.64, standard deviation of 4.65, and Mean Deviation of 3.34 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.23, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Editas Medicine will likely underperform. At this point, Editas Medicine has a negative expected return of -0.49%. Please make sure to confirm Editas Medicine's treynor ratio, as well as the relationship between the accumulation distribution and price action indicator , to decide if Editas Medicine performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.33 |
Below average predictability
Editas Medicine has below average predictability. Overlapping area represents the amount of predictability between Editas Medicine time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Editas Medicine price movement. The serial correlation of 0.33 indicates that nearly 33.0% of current Editas Medicine price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.33 | |
| Spearman Rank Test | 0.39 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Editas Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Editas Medicine reported net income of (237.09 Million). This is 169.47% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 141.52% higher than that of the company.
Editas Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Editas Medicine's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Editas Medicine could also be used in its relative valuation, which is a method of valuing Editas Medicine by comparing valuation metrics of similar companies.Editas Medicine is currently under evaluation in net income category among its peers.
Editas Medicine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Editas Medicine from analyzing Editas Medicine's financial statements. These drivers represent accounts that assess Editas Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Editas Medicine's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.8B | 609.1M | 769.5M | 104.6M | 94.1M | 89.4M | |
| Enterprise Value | 1.6B | 511.5M | 694.4M | 8.1M | 7.3M | 6.9M |
Editas Medicine Institutional Holders
Institutional Holdings refers to the ownership stake in Editas Medicine that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Editas Medicine's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Editas Medicine's value.| Shares | Susquehanna International Group, Llp | 2025-06-30 | 943.9 K | Two Sigma Advisers, Llc | 2025-06-30 | 940.6 K | Renaissance Technologies Corp | 2025-06-30 | 888.4 K | Woodline Partners Lp | 2025-06-30 | 846.4 K | Aqr Capital Management Llc | 2025-06-30 | 767.6 K | Charles Schwab Investment Management Inc | 2025-06-30 | 701.5 K | Northern Trust Corp | 2025-06-30 | 660.4 K | Goldman Sachs Group Inc | 2025-06-30 | 658.7 K | Citadel Advisors Llc | 2025-06-30 | 638.7 K | Vanguard Group Inc | 2025-06-30 | 7.2 M | Blackrock Inc | 2025-06-30 | 6.8 M |
Editas Fundamentals
| Return On Equity | -2.11 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (3.25) % | ||||
| Current Valuation | 30.21 M | ||||
| Shares Outstanding | 97.62 M | ||||
| Shares Owned By Insiders | 0.27 % | ||||
| Shares Owned By Institutions | 49.50 % | ||||
| Number Of Shares Shorted | 11.83 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 13.10 X | ||||
| Price To Sales | 3.81 X | ||||
| Revenue | 32.31 M | ||||
| Gross Profit | (64.78 M) | ||||
| EBITDA | (233.11 M) | ||||
| Net Income | (237.09 M) | ||||
| Cash And Equivalents | 452.56 M | ||||
| Cash Per Share | 6.59 X | ||||
| Total Debt | 35.03 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 12.67 X | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (210.28 M) | ||||
| Short Ratio | 6.38 X | ||||
| Earnings Per Share | (2.35) X | ||||
| Target Price | 5.43 | ||||
| Number Of Employees | 246 | ||||
| Beta | 2.19 | ||||
| Market Capitalization | 176.69 M | ||||
| Total Asset | 341.59 M | ||||
| Retained Earnings | (1.47 B) | ||||
| Working Capital | 212.09 M | ||||
| Current Asset | 144.99 M | ||||
| Current Liabilities | 6.92 M | ||||
| Net Asset | 341.59 M |
About Editas Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.